Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2Phase EARLY_PHASE1 1Phase 1 1

Status

Completed 7Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 7

Sponsor

Cancer Type

Tumor-Agnostic 3Dermatologic 2CNS 2Sarcoma 1Head & Neck 1

Conditions

Melanoma 9Neoplasms 7Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Glioblastoma 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Sarcoma 3Prostatic Neoplasms 3Glioma 3Fallopian Tube Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Astrocytoma 3Skin Neoplasms 2Pancreatic Neoplasms 2Oligodendroglioma 2Neoplasms, Plasma Cell 2Myelodysplastic Syndromes 2Lung Neoplasms 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Head and Neck Neoplasms 2Central Nervous System Neoplasms 2Brain Neoplasms 2Uveal Melanoma 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Testicular Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79Bevacizumab 75pembrolizumab 74Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Completed × Neoplasms × poly ICLC × Clear all
NCT06614140 2026-04-22

Personalized Neoantigen Cancer Vaccine for Patients With Solid Tumors

Seqker Biosciences, Inc.

Phase 1/2 Completed
8 enrolled
Tumor-Agnostic

Neoplasms

NCT01188096 2023-06-12

Poly-ICLC

Wake Forest University Health Sciences

Phase 2 Completed
23 enrolled 11 charts
CNS

Brain Neoplasms, Glioma, Neoplasms

NCT02721043 2021-01-11

Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies

Icahn School of Medicine at Mount Sinai

Phase 1 Completed
13 enrolled
Tumor-Agnostic

Neoplasms

NCT02423863 2020-12-17

Poly-ICLC

Oncovir, Inc.

Phase 2 Completed
26 enrolled
DermatologicHead & NeckSarcoma

Head and Neck Neoplasms, Melanoma, Neoplasms, Sarcoma

NCT01079741 2018-02-13

Safety Study of Adjuvant Vaccine to Treat Melanoma Patients

Icahn School of Medicine at Mount Sinai

Phase 1/2 Completed
34 enrolled 10 charts
Dermatologic

Melanoma, Neoplasms, Skin Neoplasms, Carcinogenesis

NCT01734564 2017-04-11

Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors

Clinica Universidad de Navarra, Universidad de Navarra

Phase 2 Completed
15 enrolled
Tumor-Agnostic

Neoplasms

NCT00874861 2015-12-08

HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas

University of Pittsburgh

Phase EARLY_PHASE1 Completed
10 enrolled
CNS

Astrocytoma, Neoplasms, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡